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November 20/27, 2012:2255–60would the additional cost and risks of these agents be justified (4). In
ddition, although we did not observe serious adverse effects of any
egimen, the study was not adequately powered to confirm equiva-
ence in safety of these treatment approaches.
In conclusion, monotherapy with intravenous iron should be regarded
s an efficient treatment option for ID in advanced stages of HF.
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Figure 1 Time Course and Degree ofAnemia Correction Between the 2 Groups
Both treatment regimens induced significant increase in hemoglobin (Hgb) val-
ues; it became apparent after 2 weeks of therapy and was preserved at the
end of the 12-week follow-up period. The magnitude of the treatment effect
was similar with both regimens.dvice on the statistical analysis.
With a Bioabsorbable Ring in Young
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Atrioventricular Valve Annular Remodeling
ChildrenTo the Editor: Atrioventricular (AV) valve repair for regurgitation has
been shown to be preferable to valve replacement in young children
(1). Besides valvuloplasty technique, annulus reduction and stabiliza-
ion with a ring have been demonstrated to be necessary to maintain
ffective leaflet coaptation. In young children, however, placement of
permanent annuloplasty ring is rarely performed because it carries
he risk that a re-operation will likely be required as the child grows.
The concept of annuloplasty with biodegradable material, as an
djunct to AV valve repair, is not new. More recently, a flexible
ntra-annular AV valve ring that is constructed of absorbable
iopolymer has been introduced for mitral valve (MV) and
ricuspid valve repair (2,3). Unlike rigid or semirigid rings, this
ew device is a partial ring made of flexible material, which loses
ensile strength as the ring material absorbs, thus potentiallyata available on outcomes of absorbable ring implantation in
oung children with complex congenital heart disease (CHD).
Six children (4 months to 8 years, median age: 5.4 years) with
HD and severe AV valve regurgitation underwent AV valve
lasty and insertion of a biodegradable annuloplasty ring (Bioring
A, Lonay, Switzerland). Four children had previously had AV
anal defect repair (2 had associated heterotaxy syndrome and 1
hone’s complex), 1 a dysplastic MV, and another had hypoplastic
eft heart syndrome. Food and Drug Administration approval for
evice implantation was obtained for all patients under compas-
ionate use exemption. Institutional review board approval and
nformed consent were obtained on all patients.
There were no perioperative deaths or complications such as AV
lock or coronary compromise. By early post-operative echocardi-
graphy, the AV valve anteroposterior (AP) and lateral diameters,
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November 20/27, 2012:2255–60areas, and related z-scores were significantly reduced in all 6
patients (p  0.05 for all variables) and increased—while remain-
ng in the normal range—during the follow-up period (Fig. 1).
his reduction was more pronounced on the AP diameter, thus
reating the more typical oval-shaped AV valve annulus.
During a mean follow-up of 42 months (range: 26 to 48
onths), there were no deaths, late-onset arrhythmias, or ventric-
lar dysfunction. Four patients required reoperation, 2 nonrelated
o the AV valve (aortic valve replacement and Fontan completion).
ne patient with a dysplastic MV required reoperation for mitral
tenosis due to recurrent endocardial fibroelastosis. None of the
ther 5 patients had evidence of significant stenosis, with a mean
ost-operative, and at latest follow-up, inflow gradient of 2.0 
.5 mm Hg and 2.7  4.3 mm Hg, respectively. One patient with
n AV canal defect was reoperated on late for dehiscence of the
uperior bridging leaflet of the left AV valve. This leaflet had been
etached and repositioned to eliminate subaortic obstruction. In
oth redo patients, the bioring was fully reabsorbed and subsituted
y fibrotic tissue located in the intra-annular position. One patient
ith AV canal redeveloped significant AV valve regurgitation 2
ears after repair, but remains asymptomatic with stable left
entricular dimensions and function.
Valve repair in children is challenging due to the complexity of
he underlying anatomic abnormalities and growth of the valvular
tructures over time. Unlike adults, implanting an annuloplasty
ing is usually not performed in young children due to the risk of
cquired stenosis with growth. We have evaluated our results with
he bioring in 6 pediatric patients with complex CHD and severe
V valve regurgitation. In our series, all patients had a significant
eduction and normalization of the annular measurements after
ing implantation. We did, however, observe annular growth over
ime, which was proportional to somatic growth because the z-scores
emained normal, and with a more oval-shaped annulus than before
alvuloplasty (Fig. 1).
The pediatric experience with absorbable annuloplasty ring im-
lantation has been primarily in Europe, where this device is available
or clinical use. Kalangos et al. (4) recently updated their experience
Figure 1 Mitral Annulus Z-Scores
Progression of the left atrioventricular valve anteroposterior diameter, lateral dimeith this device in children with rheumatic MV disease. The use of abiodegradableMV ring resulted in a significantly lower mean gradient
during the first year of implantation compared with the Carpentier-
Edwards ring. However, the mean age of the patients in this study was
11.8 years at repair, which is significantly older than our study
population. A more recent report on 11 children (median age: 4.5
years) undergoing tricuspid valve repair with the bioring demonstrated
tricuspid annular growth over time (3).
In summary, we have used an absorbable annuloplasty partial
ing in 6 children with complex CHD and achieved a competent
V valve with normalization of the AP and lateral diameters, area,
nd z-scores. During a median follow-up of 42 months, reduction
f those parameters remains significant, and the annulus area has
ncreased appropriate to somatic growth. This time period is
mportant because the prosthesis is predicted to be absorbed after
months of implantation. Our initial experience and the published
xperience in Europe indicate that a larger clinical trial with this
ing is warranted.
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Letters to the Editor
“Super-Responders”
and “Hypo-Responders”
Neglecting the Obvious Question?
Hsu et al. (1) reported on the predictors of “super-response” (defined
y ejection fraction) to cardiac resynchronization therapy (CRT) and
he association with morbidity and mortality. By design, the study
equired paired echocardiographic studies (baseline and 12 months),
hich inevitably led to the exclusion of 337 (31%) patients random-
zed to CRT-D in the MADIT-CRT (Multicenter Automatic
efibrillator Implantation Trial with Cardiac Resynchronization
herapy) study (2). The authors rightly acknowledged the potential
or selection bias in favor of CRT, preferentially “selecting for a
uper-response group.” However, it is the exclusion of patients who
ay have perished within the first 12 months (perhaps due to adverse
esponse to CRT) that is of more concern, as the adverse effects of
RT may be well underestimated.
There were 74 deaths in the 1,089 patients (6.8%) randomized
o CRT in the MADIT-CRT study over an average follow-up of
.4 years (29 months) (2). This is comparable to the 53 deaths in
he 731 patients (7.3%) randomized to the implantable
ardioverter-defibrillator (ICD)-only group—an annualized mor-
ality rate of about 3%. There were 25 deaths in the subgroup of
52 patients in the current analysis by Hsu et al. (1). The majority
of deaths (48%) occurred in the “hypo-responders” (12 deaths in
190 hypo-responders, or 6.3%) over a median follow-up of 15.2
months following the 12-month echocardiographic study (i.e.,
from 12 to 27 months of follow-up)—almost double the annual-
ized mortality rate in the ICD-only group in the MADIT-CRT
study (assuming linear mortality rates).
However, even this doubling of mortality rates may have
underestimated the adverse effects of CRT in hypo-responders. By
the process of deduction, of the 74 deaths in the MADIT-CRT
study, only 25 deaths were accounted for in the current study (1).
Hence, the other 49 deaths must have occurred either in the 337
patients who were not included in the current analysis, and/or in
the last 2 months of follow-up (27 to 29 months) in the 752
patients included in the current study. That the majority of deaths
(49 of the 74 deaths) may have occurred in the minority of patients
(n  337) would infer either a much higher mortality rate among
hypo-responders (if the proportion of hypo-responders is similar inthe 337 patients) and/or a much higher proportion of hypo-
responders (if mortality rate among hypo-responders is similar to
the current report). I would urge the authors to present more data
on these deaths to clarify the risk of CRT among hypo-responders.
Finally, the data presented by Hsu et al. (1) indicate that
hypo-responders are more likely to have right bundle branch block
and shorter QRS duration (150 ms), which is consistent with
other published reports (3,4). As physicians compelled by the oath
of primum non nocere, and facing mounting evidence suggesting
limited benefit of CRT in patents with these characteristics (5),
should we not be asking the next obvious question: if there is no
evidence of benefit, is there evidence of harm?
*Sern Lim, MD
*University Hospital Birmingham NHS Trust
Edgbaston
Birmingham B15 2TH
United Kingdom
E-mail: hsern@doctors.net.uk
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Reply
We appreciate the interest of Dr. Lim in our study of super-
response to cardiac resynchronization therapy involving patients
enrolled in the MADIT-CRT trial (Multicenter Automatic De-
fibrillator Implantation Trial with Cardiac Resynchronization
Therapy) (1). We thank him for his thoughtful review of our paper
and his inquiry involving overall mortality in our study.
Dr. Lim is correct that 74 of 1,089 patients (6.8%) randomized to
CRT died during an average follow-up of 29 months in the original
MADIT-CRT trial (2). In our sub-analysis (1), there were 25 deaths
in the subgroup of 752 patients (3.3%) studied over a median
follow-up of 15.2 months. However, Dr. Lim does not have access to
the primary data when he calculated crude mortality rates to draw
comparisons between hypo-responders from our study versus im-
plantable cardioverter-defibrillator (ICD) recipients from the original
MADIT-CRT trial. To clarify, in the ICD-only trial arm, 30 of 623
patients (4.8%) with left ventricular ejection fraction (LVEF) mea-
surements at both baseline and 12-month echocardiograms subse-
quently died, compared with 25 of 752 patients (3.3%) in our study of
CRT-D recipients. Therefore, to compare a crude mortality risk of
